A Pharmacokinetic Study of Minocycline in Male and Female Volunteers

Acne Clinical Trial

Official title:

An Open-label, Multiple Dose Study to Assess the Pharmacokinetic Profile of Minocycline From FMX-101 Foam (4%) in Male and Female Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02250859
• Other study ID #: FMX101-1
• Status: Completed
• Phase: Phase 1
• Start date: September 2014
• Est. completion date: January 2015

Study information

• Verified date: February 2021
• Source: Foamix Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the pharmakokinetic profile of Minocycline in FMX-101 4% foam product in male and female some of which are with acne

Description:

This is an open-label, single-center, non-randomized, multiple-administrations study in males and females, some of which are with acne.

Twelve (12) subjects will be enrolled to receive a daily dose of topical FMX-101 minocycline (4%) foam for sixteen consecutive days.

Each subject will undergo screening procedures within 21 days prior to dosing, to assess his eligibility to participate in the study, including a dermatological assessment of the acne severity and distribution (for subjects with acne).

On Days 1, 2, 3, 7, 9, 11, 14, 16 and 17 blood will be drawn for PK An End-of Study/Safety Follow-up visit will take place on 7-10 days after last dose, which will also include a dermatological assessment of response to treatment

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: January 2015
• Est. primary completion date: December 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

1. Men and women between 18 and 35 years (inclusive) of age.

2. Clear skin or facial acne of any severity, currently untreated

3. Otherwise healthy subjects

4. Subjects who provide written informed consent to participate in the study.

5. Women of childbearing potential who are willing to use 2 reliable methods of contraception or practice abstinence during the study period or be surgically sterilized and agree to undergo repeated pregnancy tests.

6. Body Mass Index (BMI) 19.0 to <30.0 kg/m2 and weight ranging between 60-90 kg (males) and 50-85 (females).

7. Non-smoking and no use of any tobacco or nicotine products (by declaration) for a period of at least 6 months prior to screening visit

8. Subjects in general good health in the opinion of the investigator as determined by medical history, vital signs, ECG and a physical examination.

9. Shaven facial hair (males)

10. Negative HIV, Hepatitis B and Hepatitis C serology tests at screening.

11. No clinically significant abnormalities in hematology, blood chemistry, or urinalysis lab tests at screening.

12. No known history of alcohol or drug abuse. Negative urinary screen for drugs of abuse determined within 21 days of the start of the study (screening visit).

13. Willingness to minimize exposure to sun for 20 days after first dosing

14. Subjects must be able to understand the requirements of the study and must be willing to comply with the requirements of the study

Exclusion Criteria:

1. Documented history or ongoing symptoms of significant neurological, renal, cardiovascular, respiratory (asthma), endocrinological, gastrointestinal, hematopoietic disease, neoplasm or any other clinically significant medical disorder, which in the investigator's judgment contraindicate administration of the study medications.

2. Known or suspected pregnancy or lactation or planned pregnancy during the study duration (females)

3. Use of topical antibiotics or topical corticosteroids for acne treatment within the past 2 weeks.

4. Use of systemic corticosteroids within the past 4 weeks.

5. Use of systemic retinoids (e.g. isotretinoin) within the past 6 months.

6. Concurrent use of medications known to be photosensitizers because of the possibility of augmented photosensitivity.

7. History or evidence of skin conditions other than acne (eg, eczema) that would interfere with the subject's participation in the study.

8. Use of any prescription or over-the-counter (OTC) medications, vitamins and herbal or dietary supplements within 14 days prior to dosing. Paracetamol or ibuprofen for symptomatic relief of pain is allowed until 24 hours prior to the study drug administration.

9. Dermatological conditions which might have an effect upon dermal application, e.g.:

Psoriasis, mycosis fungoides, widespread acne, facial or back dermatophytosis, severe hyperhydrosis, chronic or recurrent skin infections, ichtyosis

10. Excessive hair in the intended application areas

11. Current or recent (within 1year) drug or alcohol abuse.

12. Known contraindication, hypersensitivity and/or allergy to the study drug or its excipients.

13. Subjects with significant allergic response to other drugs

14. Any acute illness (e.g. acute infection) within 48 hours prior to the first study drug administration, which is considered of significance by the Principal Investigator.

15. Participation in another clinical trial with drugs received within 3 months prior to dosing (calculated from the previous study's last dosing date).

16. Subjects who donated blood in the three months or received blood or plasma derivatives in the six months preceding study drug administration.

17. Subjects unable to communicate well with the investigators and CRC staff (i.e., language problem, poor mental development or impaired cerebral function).

18. Subjects who are non-cooperative or unwilling to sign consent form.

Related Conditions & MeSH terms

• Acne

Intervention

Drug:
• FMX101, Minocycline 4% foam
FMX101, Minocycline 4% foam to be applied twice daily for 16 consecutive days

Locations

Country	Name	City	State
Israel	Sourasky Medical Center, Clinical Research Center	Tel-Aviv

Sponsors (1)

Lead Sponsor	Collaborator
Foamix Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	adverse events	AEs will be assessed starting from informed consent signature until end of study)	22-25 days
Primary	irritation and local reaction	The application area will be examined for irritation and local reaction	16 days
Primary	Change from baseline in vital signs	sitting BP, HR, RR, oral temperature	22-25 days
Primary	Cmax	will be assessed after 1 and 16 days of dosing	16 days
Primary	Tmax	will be assessed after 1 and 16 days of dosing	16 days
Primary	AUCT	will be assessed after 1 and 16 days of dosing	16 days
Primary	T½	will be assessed after 1 and 16 days of dosing	16 days